Signals, Powered By EquityPandit
Dr Reddy’s Laboratories has received establishment inspection report for its Cuernavaca facility in Mexico, from the US health regulator.
In a filing to BSE the company stated, “..we have received an Establishment Inspection Report (EIR) from the USFDA, for the above-referred facility.” Dr Reddy in an earlier regulatory filing stated that, audit of its active pharmaceutical ingredient (API) Cuernavaca plant in Mexico, by the United States Food and Drug Administration (USFDA) was completed with zero observations.
Moreover, as per the USFDA regulations an EIR is issued to a company dealing inspection findings, only after the completion of an inspection of a facility.
